Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last581 to 600 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Omega-3 vs Placebo Omega-3: Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only) | 166 of 7,740 135 of 7,740 | 0.4 points -0.0 to 0.8 | 15,480 | NCT00135226 ASCEND: A Study of Cardiovascular Events iN Diabetes |
| ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Coronavirus Disease 2019 (COVID-19) | 200 of 7,762 440 of 7,696 | -3.1 points -3.8 to -2.5 | 15,458 | NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
| GSK1437173A Group vs Placebo Group: Number of Subjects With Fatal SAEs | 208 of 7,695 221 of 7,710 | -0.2 points -0.7 to 0.4 | 15,405 | NCT01165177 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older |
| GSK1437173A Group vs Placebo Group: deaths from any cause | 11 of 7,695 15 of 7,710 | -0.1 points -0.2 to 0.1 | 15,405 | NCT01165177 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older |
| GSK1437173A Group vs Placebo Group: Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine | 43 of 7,695 25 of 7,710 | 0.2 points 0.0 to 0.5 | 15,405 | NCT01165177 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older |
| GSK1437173A Group vs Placebo Group: serious adverse events | 727 of 7,695 731 of 7,710 | -0.0 points -1.0 to 0.9 | 15,405 | NCT01165177 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older |
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of RT-PCR-Confirmed RSV Mediated LRTD During the Second Year | 16 of 10,031 29 of 5,011 | -0.4 points -0.7 to -0.2 | 15,042 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV Mediated ARI During the Second Year | 39 of 10,031 44 of 5,011 | -0.5 points -0.8 to -0.2 | 15,042 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| CSL's IVV vs Placebo: serious adverse events | 100 of 10,015 44 of 5,005 | 0.1 points -0.2 to 0.4 | 15,020 | NCT00562484 A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults |
| APPROACHES ACP Specialist Program vs Control: Hospice Enrollment | 1,095 of 7,474 1,181 of 7,358 | -1.4 points -2.6 to -0.2 | 14,832 | NCT03323502 Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support |
| APPROACHES ACP Specialist Program vs Control: deaths from any cause | 2,005 of 7,474 1,980 of 7,358 | -0.1 points -1.5 to 1.3 | 14,832 | NCT03323502 Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support |
| Asundexian vs Apixaban: Number of Participants With All-cause Mortality | 60 of 7,415 71 of 7,395 | -0.2 points -0.5 to 0.2 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Cardiovascular (CV) Death | 48 of 7,415 44 of 7,395 | 0.1 points -0.2 to 0.3 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Composite of Ischemic Stroke or Systemic Embolism | 96 of 7,415 22 of 7,395 | 1.0 points 0.7 to 1.3 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Ischemic Stroke | 85 of 7,415 21 of 7,395 | 0.9 points 0.6 to 1.1 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI) | 155 of 7,415 77 of 7,395 | 1.0 points 0.7 to 1.5 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Composite of Stroke or Systemic Embolism | 98 of 7,415 26 of 7,395 | 1.0 points 0.7 to 1.3 | 14,810 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal MI | 228 of 7,434 213 of 7,330 | 0.2 points -0.4 to 0.7 | 14,764 | NCT02697916 Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Nonfatal Stroke | 102 of 7,434 92 of 7,330 | 0.1 points -0.3 to 0.5 | 14,764 | NCT02697916 Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term |
| ASA 81mg vs ASA 325mg: Number of Participants Experiencing All-cause Death | 315 of 7,434 357 of 7,330 | -0.6 points -1.3 to 0.0 | 14,764 | NCT02697916 Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=30
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00135226-a516410a",
"title": "Omega-3 vs Placebo Omega-3: Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)",
"summary": "166 of 7740 against 135 of 7740; risk difference 0.4 points, 95% interval -0.0 to 0.8; NCT00135226, ASCEND: A Study of Cardiovascular Events iN Diabetes",
"record": "/library/comparisons/NCT00135226-a516410a",
"nct_id": "NCT00135226",
"kind": "outcome",
"participants": 15480,
"risk_difference": {
"value": 0.004005167958656332,
"lower": -0.00035421639074811884,
"upper": 0.008395516238125424
},
"group_1": "166 of 7,740",
"group_2": "135 of 7,740",
"difference": "0.4 points",
"interval": "-0.0 to 0.8",
"trial_title": "ASCEND: A Study of Cardiovascular Events iN Diabetes"
},
{
"id": "NCT05012943-38dadd9d",
"title": "ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Coronavirus Disease 2019 (COVID-19)",
"summary": "200 of 7762 against 440 of 7696; risk difference -3.1 points, 95% interval -3.8 to -2.5; NCT05012943, The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)",
"record": "/library/comparisons/NCT05012943-38dadd9d",
"nct_id": "NCT05012943",
"kind": "outcome",
"participants": 15458,
"risk_difference": {
"value": -0.031406002160962225,
"lower": -0.03774273540687387,
"upper": -0.025170527975553497
},
"group_1": "200 of 7,762",
"group_2": "440 of 7,696",
"difference": "-3.1 points",
"interval": "-3.8 to -2.5",
"trial_title": "The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=31",
"request_id": "YsTUvYbPrEGKPogA"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant